Multiple System Atrophy (MSA) is characterized by widespread neurotransmitter dysfunction affecting multiple systems simultaneously. Unlike Parkinson's disease, where dopaminergic loss is primary, MSA involves early and severe damage to autonomic and non-dopaminergic neurotransmitter systems.
MSA results from progressive degeneration of neuronal populations producing:
- Dopamine (substantia nigra, ventral tegmental area)
- Noradrenaline (locus coeruleus)
- Serotonin (raphe nuclei)
- Acetylcholine (basal forebrain, pedunculopontine nucleus)
- GABA (Purkinje cells, striatal interneurons)
This multi-system involvement explains the diverse clinical features beyond parkinsonism.
MSA produces severe sympathetic noradrenergic dysfunction that distinguishes it from other Parkinsonian disorders. Postganglionic sympathetic neurons undergo progressive degeneration, leading to:
-
Norepinephrine depletion: Loss of sympathetic nerve terminals in heart, blood vessels, and skin results in profound norepinephrine deficiency. This manifests as severe orthostatic hypotension due to inability to compensate for upright posture.
-
Cardiac denervation: ¹²³Imetaiodobenzylguanidine (MIBG) scintigraphy reveals complete cardiac sympathetic denervation in MSA, contrasting with partial denervation seen in Parkinson's disease.
-
Vasomotor dysfunction: Impaired vasoconstrictor responses due to loss of sympathetic vascular innervation leads to supine hypertension and orthostatic hypotension—a hallmark autonomic failure pattern in MSA.
The parasympathetic nervous system is equally compromised in MSA:
-
Bladder dysfunction: Detrusor overactivity results from loss of inhibitory control from the basal ganglia and pontine micturition center. Urodynamic studies show involuntary detrusor contractions in >90% of MSA patients.
-
Gastrointestinal dysmotility: Severe gastroparesis and colonic hypomotility result from vagal and enteric nervous system involvement, causing early satiety, nausea, and constipation.
-
Sexual dysfunction: Erectile dysfunction often precedes motor symptoms in male MSA patients, reflecting autonomic involvement.
The dopaminergic deficit in MSA includes:
- 60-80% neuronal loss in substantia nigra
- Severe putaminal denervation — often more severe than PD
- Loss of dopaminergic terminals in the striatum
Unlike PD, MSA patients show poor levodopa response because:
- Concurrent loss of post-synaptic striatal neurons — the target cells are degenerating
- Denervation supersensitivity does not develop — due to rapid disease course
- Multiple neurotransmitter deficits — dopamine loss is not isolated
See: Striatonigral degeneration in MSA
flowchart TD
A"Nigral Dopaminergic<br/>Neuron Loss" --> B"Striatal<br/>Denervation"
A --> C"Putaminal<br/>Neuron Loss"
B --> D"Bradykinesia<br/>Rigidity"
C --> E"Poor Levodopa<br/>Response"
style A fill:#ffcdd2,stroke:#333
style D fill:#e1f5fe,stroke:#333
The locus coeruleus (LC) is severely affected in MSA:
- Early and severe neuronal loss (>80%)
- Widespread noradrenergic denervation of cortical and subcortical targets
- Correlation with autonomic dysfunction
Noradrenergic deficit contributes to:
| Symptom |
Mechanism |
| Orthostatic hypotension |
Impaired sympathetic vasoconstriction |
| Urinary dysfunction |
Detrusor overactivity |
| Sleep disorders |
REM sleep behavior disorder |
| Cognitive deficits |
Prefrontal dysfunction |
The dorsal and median raphe nuclei show:
- Substantial neuronal loss (50-70%)
- Reduced serotonin transporter binding
- Correlation with depression in MSA patients
Serotonergic dysfunction contributes to:
- Depression — high prevalence in MSA
- Sleep architecture disruption
- Pain modulation deficits
MSA affects several cholinergic systems:
Basal Forebrain Cholinergic System:
- Nucleus basalis of Meynert degeneration
- Contributes to cognitive impairment
Brainstem Cholinergic System:
- Pedunculopontine nucleus involvement
- Contributes to gait dysfunction and falls
Spinal Autonomic Circuits:
- Preganglionic autonomic neuron loss
- Contributes to autonomic failure
The cholinergic deficit in MSA contributes to:
- Executive dysfunction
- Attention deficits
- Memory impairment (less severe than cortical dementias)
The neurotransmitter deficits in MSA are not independent:
flowchart TD
subgraph "Primary Lesions"
SN"Substantia Nigra<br/>Dopamine ↓"
LC"Locus Coeruleus<br/>Noradrenaline ↓"
RN"Raphe Nuclei<br/>Serotonin ↓"
BF"Basal Forebrain<br/>Acetylcholine ↓"
end
subgraph "Clinical Manifestations"
MOTOR"Motor Symptoms"
AUTON"Autonomic Failure"
COG"Cognitive/Behavioral"
end
SN --> MOTOR
LC --> AUTON
RN --> COG
BF --> COG
SN --> AUTON
LC --> AUTON
style MOTOR fill:#e1f5fe,stroke:#333
style AUTON fill:#ffcdd2,stroke:#333
style COG fill:#fff3e0,stroke:#333
Autonomic dysfunction creates a self-amplifying cycle:
- Orthostatic hypotension → cerebral hypoperfusion
- Reduced cerebral blood flow → increased oxidative stress
- Oxidative stress → accelerated neurodegeneration
- Neurodegeneration → worsened autonomic failure
| Neurotransmitter |
MSA |
PSP |
PD |
| Dopamine |
+++ |
++ |
+++ |
| Noradrenaline |
+++ |
+ |
± |
| Serotonin |
++ |
+ |
± |
| Acetylcholine |
++ |
++ |
± |
Current treatment addresses symptoms:
- Dopaminergic: Modest levodopa trial, limited benefit
- Noradrenergic: Midodrine, fludrocortisone for orthostasis
- Serotonergic: SSRIs for depression
- Cholinergic: Limited options, rivastigmine occasionally used
| Target |
Approach |
Stage |
| Multiple neurotransmitter restoration |
Combined delivery |
Theoretical |
| Neuroprotective agents |
Protect remaining neurons |
Preclinical |
| Gene therapy |
Viral vector delivery |
Investigational |
Neurotransmitter imaging provides:
- DAT-PET/SPECT: Differentiates from PD (more severe putaminal loss)
- MIBG scintography: Preserved in MSA (unlike PD)
- MR spectroscopy: NAA reduction in brainstem
- Jellinger et al., Neuropathology of Multiple System Atrophy (2023)
- Kaufmann et al., Natural history of autonomic dysfunction in MSA (2022)
- Chen et al., Catecholamine deficiency in MSA pathogenesis (2021)
- Fede et al., Autonomic dysfunction in atypical parkinsonism (2020)
- Kim et al., Serotonergic dysfunction in MSA (2022)
- Wang et al., Cholinergic system involvement in MSA (2019)
- Espay et al., Noradrenergic depletion in MSA (2020)
- Rebecchi et al., Dopamine transporter imaging in MSA and PD (2021)
- Jellinger et al., Neurotransmitter deficits in MSA (1995)
- Kaufmann et al., Autonomic failure in MSA (2004)